CULLINAN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
CULLINAN THERAPEUTICS, INC. (CGEM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 69.80% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 79.30%, a 2.59% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-06-30 was 82.50%.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 77.30%.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 69.80%, a 0.71% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 70.30%, a 10.67% decline from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 78.70%, a 1.38% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 79.80%, a 4.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 69.80% 10-K · filed 2026-03-10 | |||||
| 2024-12-31 | 70.30% 10-K · filed 2026-03-10 | |||||
| 2023-12-31 | 78.70% 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | 79.10% 10-Q · filed 2023-11-08 | |||||
| 2023-06-30 | 79.10% 10-Q · filed 2023-08-10 | |||||
| 2023-03-31 | 79.30% 10-Q · filed 2023-05-11 | |||||
| 2022-12-31 | 79.80% 10-K · filed 2024-03-14 | 79.81% 10-K · filed 2023-03-09 | ||||
| 2022-09-30 | 79.50% 10-Q · filed 2023-11-08 | 82.50% 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | 82.50% 10-Q · filed 2022-08-10 | 78.80% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 77.30% 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | 76.22% 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |